Bracco MultiHance "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Bracco Diagnostics' injectable magnetic resonance imaging agent MultiHance (gadobenate dimeglumine) is "approvable" at FDA for central nervous system imaging, the firm announces Nov. 25. Bracco is highlighting higher image quality due to the gadolinium contrast agent's increased relaxivity. MultiHance is approved in the EU for CNS and liver imagin
You may also be interested in...
In its “robust, holistic hub” online, firms in the VMS product supply chain can determine their needs, “by product, solution or delivery formats,” and use a “comprehensive and unique portfolio” to “turn natural sources into shelf-ready products.”
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.